Miglustat (Zavesca®) in type 1 Gaucher disease: 5-Year results of a post-authorisation safety surveillance programme

Pharmacoepidemiology and Drug Safety

Volumn 18, Issue 9, 2009, Pages 770-777

  Hollak, Carla E M ^a   Hughes, Derralynn ^b   Van Schaik, Ivo N ^a   Schwierin, Barbara ^c   Bembi, Bruno ^d  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c ACTELION PHARMACEUTICALS LTD   (Switzerland)

^d SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

Author keywords

Miglustat; Neurological manifestations; Post authorisation safety surveillance programme; Type 1 Gaucher disease

Indexed keywords

MIGLUSTAT; 1 DEOXYNOJIRIMYCIN; DRUG DERIVATIVE; ENZYME INHIBITOR;

ADOLESCENT; ADULT; AGED; ARTICLE; BONE DISEASE; CHILD; CLINICAL FEATURE; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; ELECTROMYOGRAM; EUROPE; FEMALE; GASTROINTESTINAL SYMPTOM; GAUCHER DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; PERIPHERAL NEUROPATHY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; SIDE EFFECT; SKIN TINGLING; TREATMENT DURATION; TREMOR; WEIGHT REDUCTION; CHEMICALLY INDUCED DISORDER; HOSPITALIZATION; MIDDLE AGED; PRESCHOOL CHILD; RETROSPECTIVE STUDY; STANDARD;

1-DEOXYNOJIRIMYCIN; ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; ENZYME INHIBITORS; EUROPE; FEMALE; GAUCHER DISEASE; HUMANS; MALE; MIDDLE AGED; NERVOUS SYSTEM DISEASES; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 70450173661     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1779     Document Type: Article

References (18)

1. Cox T, Lachmann R, Hollak C, et al. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 2000; 355: 1481-1485. DOI:10.1016/S0140- 6736(00)02161-2169 (Pubitemid 30237353)
2. Elstein D, Hollak C, Aerts JM, et al. Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynorjirimycin, OGT 918) in type I Gaucher disease. J Inherit Metab Dis 2004; 27: 757-766. DOI:10.1023/ B:BOLI.0000045756.54006.17 (Pubitemid 39433603)
3. Heitner R, Elstein D, Aerts J, Weely S, Zimran A. Low-dose Nbutyldeoxynojirimycin (OGT 918) for type I Gaucher disease. Blood Cells Mol Dis 2002; 28: 127-133. DOI:10.1006/bcmd.2002.0497
4. Elstein D, Dweck A, Attias D, et al. Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement. Blood 2007; 110: 2296-2301. DOI:10.1182/blood- 2007-02-075960 (Pubitemid 47523147)
5. Zhao H, Grabowski GA. Gaucher disease: perspectives on a prototype lysosomal disease. Cell Mol Life Sci 2002; 59: 694-707. DOI:10.1007/ s00018-002-8458-y (Pubitemid 34457542)
6. Morales LE. Gaucher's disease: a review. Ann Pharmacother 1996; 30: 381-388.
7. Cox TM, Schofield JP. Gaucher's disease: clinical features and natural history. Baillieres Clin Haematol 1997; 10: 657-689. DOI:10.1016/ S0950-3536(97)80033-80039
8. Butters TD, Dwek RA, Platt FM. New therapeutics for the treatment of glycosphingolipid lysosomal storage diseases. Adv Exp Med Biol 2003; 535: 219-226.
9. Platt FM, Neises GR, Dwek RA, Butters TD. N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis. J Biol Chem 1994; 269: 8362-8365. (Pubitemid 24200254)
10. Miglustat Summary of Product Characteristics. http://www.emea. europa.eu/humandocs/Humans/EPAR/zavesca/zavesca.htm (accessed 31 March 2009).
11. Pastores GM, Barnett NL, Kolodny EH. An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment. Clin Ther 2005; 27: 1215-1227. DOI:10.1016/j.clinthera.2005.08. 004
12. Zimran A, Kay A, Gelbart T, et al. Gaucher disease. Clinical, laboratory, radiologic, and genetic features of 53 patients. Medicine 1992; 71: 337-353.
13. Hollak C, Biegstraaten M, Van Schaik IN, et al. Prevalence of polyneuropathy in adult type I Gaucher disease: a multinational prospective observational study. J Inherit Metab Dis 2007; 30(Suppl 1): 427. DOI:10.1007/s10545-007-9987-1
14. Biegstraaten M, van Schaik IN, Aerts JM, Hollak CE. 'Non-neuronopathic' Gaucher disease reconsidered. Prevalence of neurological manifestations in a Dutch cohort of type I Gaucher disease patients and a systematic review of the literature. J Inherit Metab Dis 2008; 31: 337-349. DOI:10.1007/s10545-008-0832-y
15. Giraldo P, Pocovi M, Pérez-Calvo J, Rubeo-Félix D, Giralt M. Report of the Spanish Gaucher's disease registry: clinical and genetic characteristics. Haematologica 2000; 85: 792-799.
16. Charrow J, Andersson HC, Kaplan P, et al. The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease. Arch Intern Med 2000; 160: 2835-2843. DOI:10.1001/ archinte.160.18.2835 (Pubitemid 30743862)
17. Committee for Medicinal Products for Human Use. Guideline on risk management systems for medicinal products for human use. EMEA/ CHMP/96268/2005 http://www.emea.europa.eu/pdfs/human/euleg/ 9626805en.pdf (accessed 12 December 2008).
18. Managing the risks from medical product use: creating a risk management framework. Report to the FDA Commissioner from the Task Force on Risk Management. 1999. http://www.fda.gov/oc/tfrm/ executivesummary.pdf (accessed 12 December 2008).